Linagliptin Medochemie

Linagliptin, the active ingredient in Linagliptin Medochemie, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Linagliptin Medochemie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, improving glycaemic control when combined with diet and exercise.

- Type 2 diabetes mellitus: lowers fasting plasma glucose levels. - Type 2 diabetes mellitus: reduces post‑prandial glucose excursions. - Type 2 diabetes mellitus: helps achieve target HbA1c values.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Hypersensitivity reactions: fever, chills, or eosinophilia.

Linagliptin should be used with clinical vigilance in several situations. - Renal impairment: monitor renal function; dose adjustment usually not required. - Hepatic impairment: use with caution and observe liver function tests. - Cardiovascular disease: assess heart failure risk before initiation. - Hypoglycemia risk: avoid when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Linagliptin may interact with several medicines; clinical monitoring is advised.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential. - Strong CYP3A4 inhibitors: may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin exposure. - Diuretics: monitor fluid and electrolyte balance. - ACE inhibitors: no major interaction but observe blood pressure response.